Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Absci Corporation is one of them.

Absci Corporation (NASDAQ:ABSI), founded in 2018 and headquartered in Seattle, is pioneering the integration of deep learning with high-throughput lab automation to design and optimize biologics at scale. Its Integrated Drug Creation (IDC) platform combines proprietary algorithms with protein engineering, enabling rapid development of antibody and enzyme candidates for both pharma partners and its own pipeline. The stock is among the best biotech stocks.

Absci Corporation (NASDAQ:ABSI) recently expanded its partnership with Almirall, a leading dermatology-focused pharmaceutical firm, by launching a second program targeting chronic skin diseases. This builds on the successful delivery of a functional AI-designed antibody, further validating the firm’s technology. To strengthen its dermatology pipeline, Absci also appointed experts Dr. Rodney Sinclair and Dr. David Goldberg to advise on ABS-201, an AI-designed therapy for hair loss disorders such as androgenetic alopecia, which is expected to enter clinical evaluation in early 2026.

On the technology front, the business announced collaborations with Oracle Cloud Infrastructure and AMD to enhance its AI-driven drug discovery capabilities. The AMD partnership includes a strategic investment, giving the company access to advanced chip technology and cloud resources to scale model training and data processing.

Financially, Absci Corporation (NASDAQ:ABSI) boosted its balance sheet with $64 million in equity financing during July and August 2025, extending its operational runway through mid-2028. The funding will support the advancement of key pipeline programs, including ABS-101 and ABS-201, while accelerating partnered projects and strengthening the corporation’s AI infrastructure for next-generation drug discovery.

While we acknowledge the potential of ABSI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.